The U.N.'s Angeli Achrekar reports that many clinics have closed, despite exemptions in the policy. She fears mortality will ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

Despite breakthroughs in HIV treatment and prevention worldwide, critical challenges such as stigma, unequal access and ...

But on this recent night, Cox worked the party not as a professional but as volunteer activist to commemorate National Black ...

The President's Emergency Plan for AIDS Relief has been the subject of a series of presidential orders and memos that have ...

Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...

The U.S. decision in January to freeze all funding for U.S. foreign assistance, including for the U.S. President's Emergency ...

Understand how drug use increases HIV risk and learn about prevention strategies that save lives. Medical experts explain ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Advancements in medicine and public health strategies continue to reshape the HIV landscape. The future of prevention lies in expanding access to innovative treatment options and developing new ...

In Africa, a U.S. funding loss will be critical to HIV programs in countries like Uganda, Mozambique and Tanzania.

The progress made in HIV prevention and treatment over the last two decades has been transformative, but for many in Black America, the promise of these advances remains out of reach. We are now in a ...